The Carag bioresorbable septal occluder (CBSO; CARAG AG, Baar, Switzerland) is the first interatrial septal occluder with bioresorbable framework.
The study was a single-centre, prospective, single-arm trial. Ethics committee/regulatory approvals were obtained. ClinicalTrials.gov: NCT01960491.
The CBSO is the first occluder where the metal framework has been replaced with bioresorbable poly(lactic-co-glycolic) acid (PLGA) (Figure 1). The CBSO is self-centering, with two opposing polyester covers attached to a PLGA monofilament framework. The non-bioresorbable polyester fabric is secured to the monofilaments by platinum–iridium markers/sutures. A distal ...
STATE OF THE ART
Transcatheter treatment for tricuspid valve disease
This State-of-the-Art - by F. Praz et al - reviews the available transcatheter therapies, main criteria for patient and device selection, remaining uncertainties, and future directions
November 19, 2021